Journal of Surgery Concepts & Practice ›› 2023, Vol. 28 ›› Issue (01): 17-23.doi: 10.16139/j.1007-9610.2023.01.03
• Experts forum • Previous Articles Next Articles
LU Yiming, XIONG Jianping, TIAN Yantao()
Received:
2022-11-08
Online:
2023-01-25
Published:
2023-03-27
Contact:
TIAN Yantao
E-mail:tianyantao@cicams.ac.cn
CLC Number:
LU Yiming, XIONG Jianping, TIAN Yantao. Current status and prospect of conversion therapy for far-advanced gastric cancer[J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 17-23.
[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
doi: 10.3322/caac.v71.3 URL |
[2] |
MARX V. Tracking metastasis and tricking cancer[J]. Nature, 2013, 494(7435):133-136.
doi: 10.1038/494131a |
[3] |
QIU M, ZHOU Y, ZHANG X, et al. Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients[J]. BMC Cancer, 2014, 14:823.
doi: 10.1186/1471-2407-14-823 pmid: 25380654 |
[4] |
Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)[J]. Gastric Cancer, 2023, 26(1):1-25.
doi: 10.1007/s10120-022-01331-8 |
[5] |
FUJITANI K, YANG H K, MIZUSAWA J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial[J]. Lancet Oncol, 2016, 17(3):309-318.
doi: 10.1016/S1470-2045(15)00553-7 URL |
[6] |
RUDLOFF U, LANGAN R C, MULLINAX J E, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial[J]. J Surg Oncol, 2014, 110(3):275-284.
doi: 10.1002/jso.23633 pmid: 25042700 |
[7] |
NAKAJIMA T, OTA K, ISHIHARA S, et al. Combined intensive chemotherapy and radical surgery for incurable gastric cancer[J]. Ann Surg Oncol, 1997, 4(3):203-208.
pmid: 9142380 |
[8] |
CASCINU S, SCARTOZZI M, LABIANCA R, et al. High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)[J]. Br J Cancer, 2004, 90(8):1521-1525.
doi: 10.1038/sj.bjc.6601752 |
[9] |
OKANO K, MAEBA T, ISHIMURA K, et al. Hepatic resection for metastatic tumors from gastric cancer[J]. Ann Surg, 2002, 235(1):86-91.
doi: 10.1097/00000658-200201000-00011 pmid: 11753046 |
[10] |
AL-BATRAN S E, HOMANN N, PAULIGK C, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial[J]. JAMA Oncol, 2017, 3(9):1237-1244.
doi: 10.1001/jamaoncol.2017.0515 URL |
[11] |
SATO Y, OHNUMA H, NOBUOKA T, et al. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study[J]. Gastric Cancer, 2017, 20(3):517-526.
doi: 10.1007/s10120-016-0633-1 pmid: 27553665 |
[12] |
YAMAGUCHI K, YOSHIDA K, TANAHASHI T, et al. The long-term survival of stage Ⅳ gastric cancer patients with conversion therapy[J]. Gastric Cancer, 2018, 21(2):315-323.
doi: 10.1007/s10120-017-0738-1 |
[13] |
SYM S J, CHANG H M, RYU M H, et al. Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer[J]. Ann Surg Oncol, 2010, 17(4):1024-1032.
doi: 10.1245/s10434-009-0838-1 pmid: 19941081 |
[14] | 张维汉, 胡建昆. 胃癌腹膜转移诊治现状[J]. 中华胃肠外科杂志, 2021, 24(3):204-207. |
ZHANG W H, HU J K. Current status of diagnosis and treatment of gastric cancer peritoneal metastasis[J]. Chin J Gastrointest Surg, 2021, 24(3):204-207. | |
[15] |
SUZUKI T, TANABE K, TAOMOTO J, et al. Preliminary trial of adjuvant surgery for advanced gastric cancer[J]. Oncol Lett, 2010, 1(4):743-747.
pmid: 22966373 |
[16] |
ISHIGAMI H, YAMAGUCHI H, YAMASHITA H, et al. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings[J]. Gastric Cancer, 20(Suppl 1):128-134.
doi: 10.1007/s10120-016-0684-3 |
[17] |
ISHIGAMI H, FUJIWARA Y, FUKUSHIMA R, et al. Phase Ⅲ trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial[J]. J Clin Oncol, 2018, 36(19):1922-1929.
doi: 10.1200/JCO.2018.77.8613 URL |
[18] |
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma[J]. Nature, 2014, 513(7517):202-209.
doi: 10.1038/nature13480 |
[19] |
VAN CUTSEM E, BANG Y J, FENG-YI F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer[J]. Gastric Cancer, 2015, 18(3):476-484.
doi: 10.1007/s10120-014-0402-y pmid: 25038874 |
[20] |
Cancer Genome Atlas Research Network, et al. Analysis Wor-king Group: Asan University, BC Cancer Agency, Integrated genomic characterization of oesophageal carcinoma[J]. Nature, 2017, 541(7636):169-175.
doi: 10.1038/nature20805 |
[21] |
BANG Y J, VAN CUTSEM E, FEYEREISLOVA A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742):687-697.
doi: 10.1016/S0140-6736(10)61121-X URL |
[22] |
CATENACCI D V T, KANG Y K, PARK H, et al. Margetuximab plus pembrolizumab in patients with pre-viously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial[J]. Lancet Oncol, 2020, 21(8):1066-1076.
doi: 10.1016/S1470-2045(20)30326-0 URL |
[23] | PENG Z, LIU T, WEI J, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase Ⅱ study[J]. Cancer Commun (Lond), 2021, 41(11):1173-1182. |
[24] | CHENG X D, XU Z Y, DU Y, et al. Phase Ⅱ study of conversion therapy using S1/paclitaxel chemotherapy plus apatinib in unresectable gastric cancer(Ahead-G325 trial)[J]. J Clin Oncol, 2017, 35(4_suppl):53-53. |
[25] |
YE Z, ZENG Y, WEI S, et al. Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer[J]. BMC Cancer, 2021, 21(1):702.
doi: 10.1186/s12885-021-08459-3 pmid: 34126957 |
[26] |
JANJIGIAN Y Y, MARON S B, CHATILA W K, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2020; 21(6):821-831.
doi: S1470-2045(20)30169-8 pmid: 32437664 |
[27] |
JANJIGIAN Y Y, KAWAZOE A, YAÑEZ P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer[J]. Nature, 2021, 600(7890):727-730.
doi: 10.1038/s41586-021-04161-3 |
[28] |
APETOH L, GHIRINGHELLI F, TESNIERE A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy[J]. Nat Med, 2007, 13(9):1050-1059.
doi: 10.1038/nm1622 pmid: 17704786 |
[29] |
CHAGANTY B K R, QIU S, GEST A, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion[J]. Cancer Lett, 2018, 430:47-56.
doi: S0304-3835(18)30328-8 pmid: 29746929 |
[30] |
VARADAN V, GILMORE H, MISKIMEN K L, et al. Immune signatures following single dose trastuzumab predict pathologic response to preoperativetrastuzumab and chemotherapy in HER2-positive early breast cancer[J]. Clin Cancer Res, 2016, 22(13):3249-3259.
doi: 10.1158/1078-0432.CCR-15-2021 pmid: 26842237 |
[31] |
TRIULZI T, REGONDI V, DE CECCO L, et al. Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit[J]. Br J Cancer, 2018, 119(12):1487-1494.
doi: 10.1038/s41416-018-0318-0 |
[32] |
STAGG J, LOI S, DIVISEKERA U, et al. Anti-ErbB-2 mAb therapy requires type Ⅰ and Ⅱ interferons and sy-nergizes with anti-PD-1 or anti-CD137 mAb therapy[J]. Proc Natl Acad Sci U S A, 2011, 108(17):7142-7147.
doi: 10.1073/pnas.1016569108 URL |
[33] |
CHEN L T, SATOH T, RYU M H, et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data[J]. Gastric Cancer, 2020, 23(3):510-519.
doi: 10.1007/s10120-019-01034-7 |
[34] |
KANG Y K, CHEN L T, RYU M H, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2022, 23(2):234-247.
doi: 10.1016/S1470-2045(21)00692-6 URL |
[35] |
JANJIGIAN Y Y, SHITARA K, MOEHLER M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294):27-40.
doi: 10.1016/S0140-6736(21)00797-2 URL |
[36] | STEIN A, PASCHOLD L, TINTELNOT J, et al. Efficacy of ipilimumab vs. FOLFOX in combination with ni-volumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: the aio intega randomized clinical trial[J]. JAMA Oncol, 2022, 8(8):1150-1158. |
[37] |
SU Z R, KANG M, SHU K S, et al. S-1 combined with apatinib and trans-arterial chemotherapy and embolization for conversion therapy of unresectable locally advanced gastric cancer[J]. J Surg Res, 2022, 270:162-168.
doi: 10.1016/j.jss.2021.09.012 URL |
[38] | LIU S F, LU C R, CHENG H D, et al. Comparison of therapeutic efficacy between gastrectomy with transarterial chemoembolization plus systemic chemotherapy and systemic chemotherapy alone in gastric cancer with synchronous liver metastasis[J]. Chin Med J (Engl), 2015, 128(16):2194-2201. |
[39] |
YOSHIDA K, YAMAGUCHI K, OKUMURA N, et al. Is conversion therapy possible in stage Ⅳ gastric cancer: the proposal of new biological categories of classification[J]. Gastric Cancer, 2016, 19(2):329-338.
doi: 10.1007/s10120-015-0575-z URL |
[40] |
HAN D S, SUH Y S, KONG S H, et al. Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases[J]. J Surg Oncol, 2013, 107(5):511-516.
doi: 10.1002/jso.23284 URL |
[41] |
YAMAGUCHI K, YOSHIDA K, TANAKA Y, et al. Conversion therapy for stage Ⅳ gastric cancer—the present and future[J]. Transl Gastroenterol Hepatol, 2016, 1:50.
doi: 10.21037/tgh URL |
[42] |
KERÄNEN I, KYLÄNPÄÄ L, UDD M, et al. Gastric outlet obstruction in gastric cancer: a comparison of three palliative methods[J]. J Surg Oncol, 2013, 108(8):537-541.
doi: 10.1002/jso.23442 pmid: 24590674 |
[43] |
JEURNINK S M, STEYERBERG E W, VAN HOOFT J E, et al. Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial[J]. Gastrointest Endosc, 2010, 71(3):490-499.
doi: 10.1016/j.gie.2009.09.042 pmid: 20003966 |
[44] |
PAVLIDIS T E, PAVLIDIS E T. Role of stenting in the palliation of gastroesophageal junction cancer: a brief review[J]. World J Gastrointest Surg, 2014, 6(3):38-41.
doi: 10.4240/wjgs.v6.i3.38 pmid: 24672648 |
[45] | 刘昊, 徐泉, 马福海, 等. 全腹腔镜胃部分离断后胃肠吻合术治疗胃癌合并幽门梗阻的临床效果[J]. 中华肿瘤杂志, 2020, 42(6):445-448. |
LIU H, XU Q, MA F, et al. The clinical value of totally laparoscopic stomach-partitioning gastrojejunostomy for malignant gastric outlet obstruction[J]. Chin J Oncol, 2020, 42(06):445-448. | |
[46] |
SPANO D, ZOLLO M. Tumor microenvironment: a main actor in the metastasis process[J]. Clin Exp Metastasis, 2012, 29(4):381-395.
doi: 10.1007/s10585-012-9457-5 URL |
[47] |
SUN K, XU R, MA F, et al. scRNA-seq of gastric tumor shows complex intercellular interaction with an alternative T cell exhaustion trajectory[J]. Nat Commun, 2022, 13(1):4943.
doi: 10.1038/s41467-022-32627-z pmid: 35999201 |
[48] |
CHEN D, LIU Z, LIU W, et al. Predicting postoperative peritoneal metastasis in gastric cancer with serosal invasion using a collagen nomogram[J]. Nat Commun, 2021, 12(1):179.
doi: 10.1038/s41467-020-20429-0 pmid: 33420057 |
[49] |
ZHU D, ZHANG T, LI Y, et al. Tumor-derived exosomes co-delivering aggregation-induced emission luminogens and proton pump inhibitors for tumor glutamine starvation therapy and enhanced type-Ⅰ photodynamic therapy[J]. Biomaterials, 2022, 283:121462.
doi: 10.1016/j.biomaterials.2022.121462 URL |
[50] |
ZHANG B, WU Q, LI B, et al. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer[J]. Mol Cancer, 2020, 19(1):53.
doi: 10.1186/s12943-020-01170-0 |
[1] | LIU Wentao, LIU Fukun. Summary and prospect of perioperative comprehensive treatment for gastric cancer in China [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 36-41. |
[2] | ZHANG Jixiang, XIE Zhihua, LI Wei, JIANG Xiaoqing. Classification of intrahepatic cholangiocarcinoma and hot topics in surgical treatment [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 478-482. |
[3] | GUAN Tao, ZHANG Ti, WANG Lu. Pulmonary metastasis of hepatocellular carcinoma: pathogenesis and therapeutic advances [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 180-184. |
[4] | . [J]. Journal of Internal Medicine Concepts & Practice, 2017, 12(06): 365-370. |
[5] | . [J]. Journal of Diagnostics Concepts & Practice, 2013, 12(03): 320-325. |
[6] | . [J]. Journal of Internal Medicine Concepts & Practice, 2012, 7(03): 210-213. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||